Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pliant Therapeutics ( (PLRX) ) just unveiled an announcement.
On October 20, 2025, Pliant Therapeutics, Inc. announced the resignation of Hans Hull as Chief Business Officer, effective immediately. The resignation was not due to any disagreements related to the company’s operations, policies, or practices, suggesting a smooth transition without internal conflict.
The most recent analyst rating on (PLRX) stock is a Hold with a $1.70 price target. To see the full list of analyst forecasts on Pliant Therapeutics stock, see the PLRX Stock Forecast page.
Spark’s Take on PLRX Stock
According to Spark, TipRanks’ AI Analyst, PLRX is a Underperform.
Pliant Therapeutics is currently facing substantial financial difficulties, with zero revenue in 2024 and ongoing net losses. These challenges are reflected in the low financial performance score. Technical analysis shows bearish trends but hints at a potential short-term rebound. Valuation remains poor due to a negative P/E ratio and lack of dividends. Additionally, a significant workforce reduction indicates further strategic challenges. Overall, these factors contribute to a low stock score, indicating high risk and limited appeal for potential investors.
To see Spark’s full report on PLRX stock, click here.
More about Pliant Therapeutics
Average Trading Volume: 847,016
Technical Sentiment Signal: Sell
Current Market Cap: $111.1M
For detailed information about PLRX stock, go to TipRanks’ Stock Analysis page.